CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Blood

Volumn 123, Issue 19, 2014, Pages 3016-3026

  Gleason, Michelle K ^a   Ross, Julie A ^a   Warlick, Erica D ^a   Lund, Troy C ^a   Verneris, Michael R ^a   Wiernik, Andres ^b   Spellman, Stephen ^c   Haagenson, Michael D ^c   Lenvik, Alexander J ^a   Litzow, Mark R ^d   Epling Burnette, Pearlie K ^e   Blazar, Bruce R ^a   Weiner, Louis M ^f   Weisdorf, Daniel J ^a   Vallera, Daniel A ^g   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c NATIONAL MARROW DONOR PROGRAM   (United States)

^d MAYO CLINIC   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC KILLER CELL ENGAGER; CD16 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD33 PROTEIN, HUMAN; FC RECEPTOR;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOLYSIS; DEGRANULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TARGET CELL; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; HL 60 CELL LINE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; RECEPTORS, IGG; SIALIC ACID BINDING IG-LIKE LECTIN 3; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84903215048     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-533398     Document Type: Article

References (53)

1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542. (Pubitemid 46595689)
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Myelodysplastic Syndromes Version 2.2014; http://www.nccn.org/professionals/physician-gls/pdf/mds.pdf (09/04/13).
3. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
4. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94(1):333-339. (Pubitemid 29300166)
5. Guimarães F, Guven H, Donati D, et al. Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia. 2006;20(5):833-839.
6. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274. (Pubitemid 40563170)
7. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223. (Pubitemid 32368034)
8. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633-640. (Pubitemid 33043908)
9. Kiladjian JJ, Bourgeois E, Lobe I, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006;20(3):463-470. (Pubitemid 43291745)
10. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816-4824. (Pubitemid 46827777)
11. Carlsten M, Baumann BC, Simonsson M, et al. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia. 2010;24(9):1607-1616.
12. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123.
13. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287.
14. Gleason MK, Verneris MR, Todhunter DA, et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11(12):2674-2684.
15. Vallera DA, Zhang B, Gleason MK, et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells Cancer Biother Radiopharm. 2013, 28(4):274-282.
16. Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013;19(14):3844-3855.
17. Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21(4):895-903.
18. Singer H, Kellner C, Lanig H, et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother. 2010;33(6):599-608.
19. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 2010;185(4):2273-2284.
20. Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res. 2005;11(10):3879-3888. (Pubitemid 40685609)
21. McCall AM, Adams GP, Amoroso AR, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999;36(7):433-445. (Pubitemid 29336224)
22. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159-166. (Pubitemid 43053538)
23. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
24. Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595-4611.
25. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240-249.
26. Hoechst B, Voigtlaender T, Ormandy L, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology. 2009;50(3):799-807.
27. Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res. 1984;8(2):239-247. (Pubitemid 14149201)
28. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167-2176.
29. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22(4):275-281.
30. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):721s-726s.
31. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166(1):678-689. (Pubitemid 32038493)
32. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49-59.
33. Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975-2987.
34. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195(3):335-341. (Pubitemid 34461491)
35. Terme M, Tomasello E, Maruyama K, et al. IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol. 2004;172(10):5957-5966. (Pubitemid 38621195)
36. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106(2):566-571. (Pubitemid 40981252)
37. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 2005;174(2):727-734. (Pubitemid 40094266)
38. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233-4244.
39. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006;116(10):2777-2790. (Pubitemid 44511641)
40. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174(8):4880-4891.
41. Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094-4104.
42. Yang R, Cai Z, Zhang Y, Yutzy WH IV, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid cells. Cancer Res. 2006;66(13):6807-6815. (Pubitemid 44085641)
43. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123-1131. (Pubitemid 43165981)
44. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439-5449.
45. Zou JX, Rollison DE, Boulware D, et al. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009;23(7):1288-1296.
46. Kordasti SY, Ingram W, Hayden J, et al. CD4+ CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110(3):847-850. (Pubitemid 47267420)
47. Kotsianidis I, Bouchliou I, Nakou E, et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia. 2009;23(3):510-518.
48. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183(2):937-944.
49. Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599-3608.
50. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296. (Pubitemid 46697910)
51. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226-6233.
52. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
53. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185-5187.